生活质量可预测铂耐药卵巢癌女性的总生存:AURELIA子研究
基于AURELIA随机试验(n=326)及独立验证集CARTAXHY(n=136)的数据,评估基线生活质量(EORTC QLQ-C30及OV28)与铂耐药卵巢癌总生存的关联。多变量Cox回归显示躯体功能(P<0.001)和腹部/胃肠道症状(P<0.001)评分与总生存显著相关,并在验证集中得到验证。躯体功能和腹部/胃肠道症状评分在临床病理因素基础上可改善总生存预测(C统计量0.71 vs 0.67)。
要点
- 躯体功能评分<67、67-93、>93三组中位总生存分别为11.0、14.7、19.3个月(P<0.001)。
- 腹部/胃肠道症状评分>44、13-44、<13三组中位总生存分别为11.9、14.3、19.7个月(P<0.001)。
- 躯体功能(P=0.02)和腹部/胃肠道症状(P=0.03)经临床病理因素调整后仍为独立预后因素。
核心结论
- 在铂耐药卵巢癌中,躯体功能和腹部/胃肠道症状评分在临床病理因素基础上可改善总生存预测。
- 该额外预后信息可能改善试验分层、医患预后沟通和临床决策。
研究设计与样本
- AURELIA随机试验(n=326)比较化疗联合或不联合贝伐珠单抗,用于识别与总生存显著相关的基线生活质量域(EORTC QLQ-C30和OV28)。
- 患者被分为良好、中等和差风险类别,切点在独立数据集CARTAXHY(n=136)中验证。
- 对显著生活质量域进行多变量Cox回归分析,调整临床病理预后因素,并使用C统计量评估额外生活质量信息。
主要发现
- 在AURELIA中,除认知功能外所有生活质量域在单变量分析中均预测总生存。
- 躯体功能(P<0.001)和腹部/胃肠道症状(P<0.001)评分在多变量模型中仍显著。
- 躯体功能高风险(评分<67)、中风险(67-93)、低风险(>93)组中位总生存分别为11.0、14.7、19.3个月(P<0.001);在CARTAXHY中分别为7.9、16.2、23.9个月(P<0.001)。
- 腹部/胃肠道症状高风险(>44)、中风险(13-44)、低风险(<13)组中位总生存在AURELIA中分别为11.9、14.3、19.7个月(P<0.001),在CARTAXHY中分别为10.5、19.6、24.1个月(P=0.02)。
- 调整临床病理因素后,躯体功能(P=0.02)和腹部/胃肠道症状(P=0.03)仍为独立预后因素;完整模型C统计量为0.71,仅生活质量因素、仅患者因素、仅疾病因素的C统计量分别为0.61、0.61、0.67。
关键数值与推荐
- 躯体功能风险分类切点:高风险评分<67,中风险67-93,低风险>93。
- 腹部/胃肠道症状风险分类切点:高风险>44,中风险13-44,低风险<13。
临床怎么用
- 原文结论指出,躯体功能和腹部/胃肠道症状评分提供的额外预后信息可能改善试验分层、医患预后沟通和临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women with platinum-resistant ovarian cancer are a heterogeneous group whose median overall survival is 12 months. We hypothesized that their quality of life (QoL) scores would be prognostic. PATIENTS AND METHODS: Data from AURELIA (n = 326), a randomized trial of chemotherapy with or without bevacizumab, were used to identify baseline QoL domains [EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 and OV28] that were significantly associated with overall survival in multivariable Cox regression analyses. Patients were classified as having good, medium, or poor risk. Cutpoints were validated in an independent dataset, CARTAXHY (n = 136). Multivariable analyses of significant QoL domains on survival were adjusted for clinicopathological prognostic factors. The additional QoL information was assessed using C statistic. RESULTS: In AURELIA, all domains, except cognitive function, predicted overall survival in univariable analyses. Physical function (P < 0.001) and abdominal/gastrointestinal symptom (P < 0.001) scores remained significant in multivariable models. In high (score <67), medium (67-93), and low (>93) risk categories for physical function, median overall survival was 11.0, 14.7, and 19.3 months, respectively (P < 0.001). In CARTAXHY, median overall survival was 7.9, 16.2, and 23.9 months (P < 0.001), respectively. For high- (>44), medium- (13-44), and low- (<13) risk categories for abdominal/gastrointestinal symptoms, median overall survival was 11.9, 14.3, and 19.7 months in AURELIA (P < 0.001) and 10.5, 19.6, and 24.1 months in CARTAXHY (P = 0.02). Physical function (P = 0.02) and abdominal/gastrointestinal symptoms (P = 0.03) remained independent prognostic factors after adjustment for clinicopathological factors. The C statistic of the full model was 0.71. For QoL factors alone, patient factors alone and disease factors alone, the C statistics were 0.61, 0.61, and 0.67 respectively. CONCLUSIONS: Physical function and abdominal/gastrointestinal symptom scores improved predictions of overall survival over clinicopathological factors alone in platinum-resistant ovarian cancer. This additional prognostic information could improve trial stratification, patient-doctor communication about prognosis, and clinical decision-making. CLINICAL TRIAL REGISTRATION: NCT00976911.
引用
- Roncolato FT, Gibbs E, Lee CK, et al. Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Ann Oncol. 2017. PMID: 28595285. doi:10.1093/annonc/mdx229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。